The benefit of H2 receptors antagonist Rupatadine in treatment for urticaria

Cover Page

Cite item


Second generation antihistamine drugs are mainly used for the therapy of patients suffering from urticaria; however, they are efficient in 45-60% of cases only. New drugs for treatment of urticaria need to be developed and implemented, and second generation antihistamine drug Rupatadine is one of them. At the same time, Rupatadine efficiently inhibits the inflammatory action of the platelet-activating factor. Due to its double action, Rupatadine used perorally in the dose of 10 mg once a day is an efficient drug for treatment of urticaria, and its safety was confirmed by clinical trials.

About the authors

A. A. Kubanov

State Research Center of Dermatovenereology and Cosmetology, Ministry of healthcare of the Russian Federation

Author for correspondence.
Russian Federation

V. V. Chikin

State Research Center of Dermatovenereology and Cosmetology, Ministry of healthcare of the Russian Federation

Russian Federation


  1. Zuberbier T., Asero R., Bindslev-Jensen C. et al. EAACI/GA2LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria. Allergy 2009; 64: 1417-1426. Литература
  2. Clive E.H., Ruth A., Malcom W. Chronic urticaria. J Am Acad Dermatol 2002; 46: 645-657.
  3. Baiardini I., Giardini A., Pasquali M. et al. Quality of life and patients’ satisfaction in chronic urticaria and respiratory allergy. Allergy 2003; 58 (7): 621-623.
  4. Reeves G.E., Boyle M.J., Bonfield J. et al. Impact of hydroxychloroquine therapy on chronic urticaria: Chronic autoimmune urticaria study and evaluation. Intern Med J 2004; 34: 182-186. 120 к № 3, 2014
  5. Staubach P., Eckhardt-Henn A., Dechene M. et al. Quality of life in patients with chronic urticaria is differentially impaired and determined by psychiatric comorbidity. Br J Dermatol 2006; 154: 294-298.
  6. Uguz F., Engin B., Yilmaz E. Quality of life in patients with chronic idiopathic urticaria: The impact of Axis I and Axis II psychiatric disorders. Gen Hosp Psychiatry 2008; 30: 453-457.
  7. O’Donnell B.F., Lawlor F., Simpson J. et al. The impact of chronic urticaria on the quality of life. Br J Dermatol 1997; 136 (2): 197-201.
  8. Kaplan A.P., Greaves M. Pathogenesis of chronic urticaria. Clin Exp Allergy 2009; 39 (6): 777-787.
  9. Zuberbier T., Asero R., Bindslev-Jensen C. et al. EAACI/GA2LEN/ EDF/WAO guideline: management of urticaria. Allergy 2009; 64: 1427-1443.
  10. Makris M., Maurer M., Zuberbier T. Pharmacotherapy of chronic spontaneous urticaria. Expert Opin Pharmacother 2013; 14 (18): 2511-2519.
  11. Leurs R., Church M.K., Taglialatela M. H1-antihista-mines: inverse agonism, anti-inflammatory actions and cardiac effects. Clin Exp Allergy 2002; 32: 489-498.
  12. Kim H., Lynde C. Impact of desloratadine on symptoms and quality of life in subjects with chronic idiopathic urticaria: a multicenter, practice-based study. Arch Drug Inf 2008; 1 (2): 63-69.
  13. Kolasani B.P., Mudium R., Reddy N. A comparative study of efficacy and safety of rupatadine versus desloratadine in patients with chronic idiopathic urticaria. As J Biomed Pharm Sci 2013; 3 (21): 42-47.
  14. Grzelewska-Rzymowska I., Gôrski P. Rupatadine: a novel second-generation antihistamine. Post Dermatol Alergol 2011; XXVIII, 6: 480-488.
  15. Kaplan A.P. Treatment of chronic spontaneous urticaria. Allergy Asthma Immunol Res 2012; 4 (6): 326-331.
  16. Curtin M.L. Current status of platelet activating factor antagonists. Exp Opin Ther Patents 1998; 8: 703-711.
  17. Kajiwara N., Sasaki T., Bradding P. et al. Activation of human mast cells through the platelet-activating factor receptor. J Allergy Clin Immunol 2010; 125: 1137-1145.
  18. Yost C.C., Weyrich A.S., Zimmerman G.A. The platelet activating factor (PAF) signaling cascade in systemic inflammatory responses. Biochimie 2010; 92 (6): 692-697.
  19. Hasan A.M., Mourtada-Maarabouni M., Hameed M.S. et al. Phosphoinositide 3-kinase gamma mediates chemotactic responses of human eosinophils to platelet-activating factor. Int Immunopharmacol 2010; 9: 1017-1021.
  20. Marques S.A., Dy L.C., Southall M.D. et al. The platelet-activating factor receptor activates the extracellular signal-regulated kinase mitogen-activated protein kinase and induces proliferation of epidermal cells through an epidermal growth factor-receptor-dependent pathway. J Pharmacol Exp Ther 2002; 300: 1026-1035.
  21. Krause K., Gimenez-Arnau A., Martinez-Escala E. et al. Platelet-activating factor (PAF) induces wheal and flare skin reactions independent of mast cell degranulation. Allergy 2013; 68: 256-258.
  22. Thomas G., Church M.K. Platelet activating factor does not release histamine from human dispersed cutaneous mast cells. Clin Exp Allergy 1990; 20: 377-382.
  23. Katayama I., Matsui S., Murota H. Platelet activation as a possible indicator of disease activity in chronic urticaria: link with blood coagulation and mast cell degranulation. J Clin Exp Dermatol Res 2013; 4: 194. doi: 10.4172/2155-9554.1000194.
  24. Asero R., Tedeschi A., Riboldi P., Cugno M. Plasma of patients with chronic urticaria shows signs of thrombin generation, and its intradermal injection causes wheal-and-flare reactions much more frequently than autologous serum. J Allergy Clin Immunol 2006; 117: 1113-1117.
  25. Rajappa M., Chandrashekar L., Sundar I. et al. Platelet oxidative stress and systemic inflammation in chronic spontaneous urticaria. Clin Chem Lab Med 2013; 51: 1789-1794.
  26. Takahagi S., Mihara S., Iwamoto K. et al. Coagulation/ fibrinolysis and inflammation markers are associated with disease activity in patients with chronic urticaria. Allergy 2010; 65: 649-656.
  27. Merlos M., Giral M., Balsa D. et al. Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF) J Pharmacol Exp Ther 1997; 280 (1): 114-121.
  28. Maiti R., Jaida J., Raghavendra B. et al. Rupatadine and levocetirizine in chronic idiopathic urticaria: a comparative study of efficacy and safety. J Drugs Dermatol 2011; 10 (12): 1444-1450.
  29. Izquierdo I., Nieto C., Ramis J. et al. Pharmacokinetics and dose linearity of rupatadine fumarate in healthy volunteers. Methods Find Exp Clin Pharmacol 1997; 19 (Suppl. A): 189-203.
  30. Queralt M., Merlos M., Giral M., Puigdemont A. Dual effect of rupatadine on edema induced by PAF and histamine in dogs: comparison with antihistamines and PAF antagonists. Drug Develop Res 1996; 39: 12-18.
  31. Church M.K. Efficacy and tolerability of rupatadine at four times the recommended dose against histamine-and PAF-induced flare responses and ex vivo platelet aggregation in healthy males. Br J Dermatol 2010; 163: 1330-1332.
  32. Izquierdo I., Merlos M., Garcia-Rafanell J. Rupatadine, a new selective histamine HI receptor and platelet activating factor (PAF) antagonist: a review of pharmacological profile and clinical management of allergic rhinitis. Drugs Today (Barc) 2003; 39: 451-468.
  33. Queralt M., Brazis P., Merlos M. et al. In vitro inhibitory effect of rupatadine on histamine and TNF-a release from dispersed canine skin mast cells and the human cell line HMC-1. Inflam Res 2000; 49: 355-360.
  34. Vasiadi M., Kalogeromitros D., Kempuraj D. et al. Rupatadine inhibits proinflammatory mediator secretion from human mast cells triggered by different stimuli. Int Arch Allergy Immunol 2010; 151 (1): 38-45.
  35. Alevizos M., Karagkouni A., Vasiadi M. et al. Rupatadine inhibits inflammatory mediator release from human laboratory of allergic diseases 2 cultured mast cells stimulated by platelet-activating factor. Ann Allergy Asthma Immunol 2013; 111 (6): 542-547.
  36. Dubertret L., Zalupca L., Cristodoulo T. et al. Once daily rupatadine improves the symptoms of chronic idiopathic urticaria: a randomised, double-blind, placebo-controlled study. Eur J Dermatol 2007; 17: 223-228.
  37. Mullol J., Bousquet J., Bachert C. et al. Rupatadine in allergic rhinitis and chronic urticaria. Allergy. 2008; 63 (Suppl 87): 5-28.
  38. Giménez-Arnau A., Izquierdo I., Maurer M. The use of a responder analyses to identify clinically meaningful differences in chronic urticaria patients following placebocontrolled treatment with rupatadine 10 and 20 mg. J Eur Acad Dermatol Venerol 2009; 23: 1088-1091.
  39. Keam S.J., Plosker G.L. Rupatadine: a review of its use in the management of allergic disorders. Drug 2007; 67 (3): 457-474.
  40. Caballero R., Valenzuela C., Longobardo M. et al. Effects of rupatadine, a new dual antagonist of histamine and platelet-activating factor receptors, on human cardiac Kv1.5 channels. Br J Pharmacol 1999; 128: 1071-1081.
  41. Barbanoj M.J., Garcia-Gea C., Morte A. et al. Central and peripheral evaluation of rupatadine, a new antihistamine/platelet-activating factor antagonist, at different doses in healthy volunteers. Neuropsychobiology 2004; 50: 311-321.
  42. Vuurman E., Theunissen E., van Oers A. et al. Lack of effects between rupatadine 10 mg and placebo on actual driving performance of healthy volunteers. Human Psychopharmacol Clin Exp 2007; 22: 289-297.
  43. Saint-Martin F., Dumur J.P., Perez I., Izquierdo I. A randomized, double-blind, parallel-group study, comparing the efficacy and safety of rupatadine (20 and 10 mg), a new PAF and HI receptor specific histamine antagonist, to loratadine 10 mg in the treatment of seasonal allergic rhinitis. J Investig Allergol Clin Immunol 2004; 14: 34-40.
  44. Guadano E.M., Serra-Batlles J., Meseguer J. et al. Rupatadine 10 mg and ebastine 10 mg in seasonal allergic rhinitis: a comparison study. Allergy 2004; 59: 766-771.
  45. Martinez-Cocera C., De Molina M., Marti-Guadano E. et al. Rupatadine 10 mg and cetirizine 10 mg in seasonal allergic rhinitis: a randomised, double-blind parallel study. J lnvestig Allergol Clin Immunol 2005; 15: 22-29.
  46. Maiti R., Rahman J., Jaida J. et al. Rupatadine and levocetirizine for seasonal allergic rhinitis. A comparative study of efficacy and safety. Arch Otolaryngol Head Neck Surg 2010; 136: 796-800.
  47. Valero A., de la Torre F., Castillo J.A. et al. Safety of rupatadine administered over a period of 1 year in the treatment of persistent allergic rhinitis. A multicentre, open-label study in Spain. Drug Safety 2009; 32: 33-42.

Copyright (c) 2014 Kubanov A.A., Chikin V.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 60448 от 30.12.2014.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies